Kissei Pharmaceutical Co., Ltd. (4547)

Name: Kissei Pharmaceutical Co., Ltd. (4547) — storico dei bilanci
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Storico di ricavi, utili e flussi di cassa dai bilanci ufficiali.

Healthcare · Wall Street (USA) · Ultimo aggiornamento: 2026-10-02

Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan and internationally. It offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of renal anemia.

Dati chiave

Capitalizzazione di mercato: JPY 155 billion
Ricavi (esercizio chiuso a 2026-03-31): JPY 97.4B
Utile netto: JPY 13.8B
Margine lordo: 47.0%
Margine netto: 14.1%

Vedi grafici interattivi e bilanci completi → Modello di valutazione (DCF) →

Conto economico annuale

Conto economico	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Entrate totali	JPY 97.4B	JPY 88.3B	JPY 75.6B	JPY 67.5B
Utile lordo	JPY 45.8B	JPY 44.1B	JPY 37.3B	JPY 32.4B
Risultato Operativo (EBIT)	(JPY 2.9B)	JPY 5.8B	JPY 4.0B	(JPY 1.1B)
Reddito netto	JPY 13.8B	JPY 12.0B	JPY 11.2B	JPY 10.5B

Fonte: bilanci pubblici della società (SEC). Verificare su SEC EDGAR prima di fare affidamento su qualsiasi cifra.

Stati patrimoniali, flussi di cassa, dati trimestrali e indici completi nel visualizzatore interattivo di 4547. /companies/us/4547

Aziende simili

4521 · Kaken Pharmaceutical Co., Ltd.

Le informazioni di questo sito sono solo a scopo educativo e informativo; non costituiscono consulenza finanziaria. Non vengono pubblicati prezzi obiettivo né raccomandazioni.

English version →Tutte le azioni

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.